Valuation: Bolt Biotherapeutics, Inc.

Market Cap 7.71M 6.85M 6.35M 5.78M 10.9M 731M 11.07M 76.31M 29.92M 382M 28.92M 28.3M 1.22B P/E 2026 *
-0.17x
P/E 2027 * -0.2x
Enterprise Value 7.71M 6.85M 6.35M 5.78M 10.9M 731M 11.07M 76.31M 29.92M 382M 28.92M 28.3M 1.22B EV / Sales 2026 *
38.5x
EV / Sales 2027 * 2.2x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day-5.66%
1 week-2.68%
Current month+8.70%
1 month+10.19%
3 months-4.53%
6 months-16.84%
Current year-26.85%
1 week 3.76
Extreme 3.76
4.68
1 month 3.1
Extreme 3.1
4.68
Current year 3.1
Extreme 3.1
7.2
1 year 3.1
Extreme 3.1
7.2
3 years 3.1
Extreme 3.1
31.2
5 years 3.1
Extreme 3.1
280.6
10 years 3.1
Extreme 3.1
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2024-05-14
Chief Executive Officer 55 2024-05-14
Chief Operating Officer 61 2024-05-14
Director TitleAgeSince
Director/Board Member 64 2020-11-30
Director/Board Member 55 2024-05-14
Chairman 56 2024-09-03
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 Sell

Chief Operating Officer

-6,850 0.3556%
9/18/26 Sell

Controller/Auditor

-4,077 0.2116%
9/18/26 Sell

Chief Executive Officer

-9,132 0.4741%
Change 5-day change 1-year change 3-year change Capi.($)
-5.66%-2.68%-31.77%-80.39% 7.71M
-6.60%-8.56%+42.79%+64.16% 65B
-4.09%-0.11%+2.31%+54.81% 51.19B
+0.03%+5.56%+10.18%+41.75% 51.2B
-1.53%+2.70%+29.72%+34.13% 43.93B
-1.34%+4.12%+16.05%+112.18% 41.96B
-5.97%-6.22%+258.21%+421.57% 38.14B
+6.53%+8.02%+15.74%+53.94% 33.24B
-0.90%-10.49%+31.48%-1.63% 25.2B
-2.76%-9.54%-16.53%-9.55% 22.03B
Average -2.23%-1.77%+35.82%+69.10% 37.19B
Weighted average by Cap. -2.30%-1.21%+43.56%+88.57%

Financials

2026 *2027 *
Net sales 200K 178K 165K 150K 283K 18.98M 287K 1.98M 777K 9.91M 751K 735K 31.58M 3.5M 3.11M 2.88M 2.62M 4.95M 332M 5.03M 34.66M 13.59M 173M 13.14M 12.86M 553M
Net income -47.4M -42.13M -39.05M -35.53M -67.05M -4.5B -68.12M -469M -184M -2.35B -178M -174M -7.48B -47.5M -42.22M -39.13M -35.61M -67.19M -4.51B -68.27M -470M -184M -2.35B -178M -174M -7.5B
Net Debt - -
Projected Income Statement - Annual - Bolt Biotherapeutics, Inc.
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
26-10-16 US$4.000 -5.66% 10,118
26-10-15 US$4.240 +6.53% 9,255
26-10-14 US$3.980 -7.12% 31,070
26-10-13 US$4.285 +1.06% 12,826
26-10-12 US$4.240 +3.16% 28,728
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Bolt Biotherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.000USD
Average target price
29.00USD
Spread / Average Target
+625.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Bolt Biotherapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. BOLT Stock